Forecast

There is no analyst data available for this company.

News Go to news feed

Sandoz: one-year investment yields around 50% return

If 100 CHF had been invested in Sandoz a year ago (closing price 48.91 CHF), the investor would now hold 2.045 shares worth 150.07 CHF at a price of 73.40 CHF on 18.08.2026. That corresponds to a value increase of 50.07 percent. The Sandoz share was first listed on 04.10.2023 at a price of 24.00 CHF; stock splits and dividends are not included in the calculation. » More on finanzen.net
Sandoz closes strategic cooperation with Henlius; shares hit 52-week high

Sandoz agreed a comprehensive partnership with Shanghai Henlius Biotech with a potential total value of up to $322 million and near-term payments of up to $100.5 million in 2026. The cooperation covers up to 10 biosimilar active substances; Sandoz will receive global commercialization rights outside China, while Henlius will take on development and manufacturing. The first tranche confirmed three products targeting evolocumab, belimumab and cetuximab, plus an option for recombinant hyaluronidase. The announcement pushed the share to a daily high of 75.56 CHF and a new 52-week high, supported by an already strong business momentum in H1 2026. » More on de.investing.com
Shanghai Henlius Biotech closes strategic cooperation with Sandoz and grants exclusive rights for up to ten candidates

According to the agreement with Sandoz, Shanghai Henlius Biotech granted exclusive rights for approval and commercialization of up to ten product candidates outside China, including indications in oncology, autoimmune diseases and ophthalmology. The partnership is intended to secure Henlius’ international expansion through Sandoz’s commercial infrastructure and support its revenue-diversification goal. The stock then rose 1.2% to HK$68.1 amid a broader upswing in the Hong Kong market. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Sandoz has already paid 0,87€ in dividends. The last payout was in April.

Financials

In the last quarter, Sandoz had revenue of 4,94Md€ and net profit of 93,42M€

(EUR)	Jun 2026	YoY
Revenue	+4,94Md	-
Gross profit	+2,30Md	-
Net profit	+93,42M	-
EBITDA	+959,02M	-

Fundamentals

Metric	Value
Market capitalization	+33,91Md€
Number of shares	432,01M
52-week high/low	+78,85€ - +25,08€
Dividend yield	+1,16%
Dividends TTM	+0,87€
Beta	0,49
P/E ratio	+60,70
PEG ratio	+0,32
P/B ratio	+4,42
P/S ratio	+3,44

Company profile

Die Sandoz Group AG entwickelt, produziert und vermarktet weltweit generische Arzneimittel und Biosimilars. Sie entwickelt, produziert und vermarktet fertige Darreichungsformen von Arzneimitteln mit kleinen Molekülen für Dritte. Darüber hinaus bietet das Unternehmen Produkte auf Protein- oder anderer Biotechnologiebasis, einschließlich Biosimilars, sowie biotechnologische Produktionsdienstleistungen und Antiinfektiva, wie pharmazeutische Wirkstoffe und Zwischenprodukte, vor allem Antibiotika, an. Das Unternehmen wurde 1886 gegründet und hat seinen Hauptsitz in Rotkreuz, Schweiz.